^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    pan-KRAS inhibitor

    Related drugs:
    3d
    J5Q-OX-JRDA: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (clinicaltrials.gov)
    P1, N=750, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C • KRAS G12D • KRAS G12 • KRAS G12S • KRAS G13
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium
    10d
    Study of AUBE00 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=130, Recruiting, Chugai Pharmaceutical | N=100 --> 130 | Trial completion date: Jun 2030 --> Dec 2029 | Trial primary completion date: Jun 2030 --> Dec 2029
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Erbitux (cetuximab)
    13d
    TLN-372-2501: A Clinical Trial to learn about the effects of TLN-372 when given Alone and in Combination with Other Anti-Tumor Agents in people with Advanced KRAS Mutant Solid Cancers (2025-523086-22-00)
    P1/2, N=20, Recruiting, Treeline Biosciences Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab)
    15d
    A study of TLN-372 in Patients with Advanced KRAS Mutant Solid Tumors. (ACTRN12626000207314)
    P1, N=50, Not yet recruiting, Treeline Biosciences, Inc.
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    17d
    20240031: AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors (2025-521707-48-00)
    P1, N=135, Recruiting, Amgen Inc.
    New P1 trial
    17d
    TLN-372-2501: A Clinical Trial to learn about the effects of TLN-372 when given Alone and in Combination with Other Anti-Tumor Agents in people with Advanced KRAS Mutant Solid Cancers (2025-523086-22-00)
    P1/2, N=20, Not yet recruiting, Treeline Biosciences Inc.
    New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab)
    1m
    AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=434, Recruiting, Amgen | Trial completion date: Oct 2030 --> Apr 2031 | Trial primary completion date: Oct 2027 --> Apr 2028
    Trial completion date • Trial primary completion date • First-in-human
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS wild-type
    |
    Keytruda (pembrolizumab) • Vectibix (panitumumab)
    1m
    BBO-11818 in Adult Subjects With KRAS Mutant Cancer (clinicaltrials.gov)
    P1, N=387, Recruiting, TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | N=287 --> 387
    Enrollment change • First-in-human
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C • KRAS G12D • KRAS G12 • KRAS G12S
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • oxaliplatin • leucovorin calcium
    2ms
    A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration (clinicaltrials.gov)
    P1/2, N=334, Recruiting, Jacobio Pharmaceuticals Co., Ltd. | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    2ms
    A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (clinicaltrials.gov)
    P1, N=26, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=190 --> 26
    Enrollment closed • Enrollment change • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • oxaliplatin • leucovorin calcium • Zumrad (sasanlimab) • PF-07284892
    2ms
    A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) (clinicaltrials.gov)
    P1, N=71, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Mekinist (trametinib) • BI 1701963
    4ms
    JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration (clinicaltrials.gov)
    P1/2, N=294, Recruiting, Jacobio Pharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)